SiRNA RSS

Filtered By:
Specialty: Cancer & Oncology
Cancer: Bone Cancers

This page shows you your search results in order of date.

Order by Relevance | Date

Total 114 results found since Jan 2013.

Co-delivery of curcumin and si-STAT3 with a bioinspired tumor homing for polydopamine nanoparticles for synergistic osteosarcoma therapy
ConclusionThis study revealed that CPDA/siSTAT3@SCM NPs can target drug delivery by biomimetic multifunctional nanoparticles to treat OS through chemo-gene combined therapy.
Source: Cancer Nanotechnology - June 20, 2023 Category: Cancer & Oncology Source Type: research

Vitamin D inhibits osteosarcoma by reprogramming nonsense-mediated RNA decay and SNAI2-mediated epithelial-to-mesenchymal transition
In this study, we assessed the impact of vitamin D and its receptor (VDR) on NMD-ROS-EMT signaling in in vitro and in vivo osteosarcoma animal models. Initiation of VDR signaling facilitated the enrichment of EMT pathway genes, after which 1,25(OH)2D, the active vitamin D derivative, inhibited the EMT pathway in osteosarcoma subtypes. The ligand-bound VDR directly downregulated the EMT inducer SNAI2, differentiating highly metastatic from low metastatic subtypes and 1,25(OH)2D sensitivity. Moreover, epigenome-wide motif and putative target gene analysis revealed the VDR’s integration with NMD tumorigenic and immunogenic ...
Source: Frontiers in Oncology - May 9, 2023 Category: Cancer & Oncology Source Type: research

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA
ConclusionDOX/siSUR-PLGA@MSCM NPs can show improved therapeutic effects in osteosarcoma patients due to the combination of a chemotherapeutic drug and gene therapy based on their good tumor targeting and biosafety.
Source: Frontiers in Oncology - January 23, 2023 Category: Cancer & Oncology Source Type: research

DEPDC1 as a crucial factor in the progression of human osteosarcoma
ConclusionsCollectively, this study demonstrated thatDEPDC1 is a critical driver in the promotion of osteosarcoma progression and results in poor patient prognosis. Genetically targeting or pharmacologically inhibitingDEPDC1 may serve as a promising strategy for treating human osteosarcoma.
Source: Cancer Medicine - December 7, 2022 Category: Cancer & Oncology Authors: Lin Shen, Han Li, Ronghan Liu, Chendan Zhou, Morgan Bretches, Xuan Gong, Laitong Lu, Ying Zhang, Kai Zhao, Bin Ning, Shang ‐You Yang, Aijun Zhang Tags: RESEARCH ARTICLE Source Type: research

lncRNA JPX modulates malignant progress of osteosarcoma through targeting miR-33a-5p and PNMA1 regulatory loop
In this study, we found that lncRNA JPX was up-regulated in OS tissues and cells. We subsequently examined the functional role of JPX in OS cells through knocked-down JPX by using siRNA. JPX down-regulation was observed to suppress OS cell proliferation, migration and invasion. Furthermore, it was verified that JPX acts as a sponge for miR-33a-5p, and that JPX regulated OS cell proliferation, migration and invasion through miR-33a-5p. Moreover, down-regulation of miR-33a-5p in OS contributed to PNMA1 upregulation, and PNMA1 depletion inhibited OS cell proliferation, migration and invasion in vitro. Taken together, our data...
Source: Translational Oncology - September 6, 2022 Category: Cancer & Oncology Authors: Wei Xiong Dan Liu Xi Chen Leiting Liu Weihong Xiao Source Type: research

Targeting podoplanin for the treatment of osteosarcoma
CONCLUSIONS: Targeting PDPN with a neutralizing antibody against PDPN-CLEC-2 without ADCC and CDC is a novel therapeutic strategy for PDPN-positive OS.PMID:35381070 | DOI:10.1158/1078-0432.CCR-21-4509
Source: Clinical Cancer Research - April 5, 2022 Category: Cancer & Oncology Authors: Ai Takemoto Satoshi Takagi Takao Ukaji Nobuhiko Gyobu Mamoru Kakino Miho Takami Asami Kobayashi Marie Lebel Tokuichi Kawaguchi Minoru Sugawara Kazue Tsuji-Takayama Kenji Ichihara Yuki Funauchi Keisuke Ae Seiichi Matsumoto Yoshiya Sugiura Kengo Takeuchi Te Source Type: research

TPX2 regulated by miR-29c-3p induces cell proliferation in osteosarcoma via the AKT signaling pathway
Oncol Lett. 2022 May;23(5):143. doi: 10.3892/ol.2022.13262. Epub 2022 Mar 11.ABSTRACTThe present study aimed to investigate the significance of targeting protein for Xenopus kinesin-like protein 2 (TPX2) expression in osteosarcoma. First, the TPX2 expression and survival analysis data were evaluated from The Cancer Genome Atlas (TCGA) database. Next, reverse transcription-quantitative PCR was used to explore the expression of TPX2 in osteosarcoma tissues. The observed potential target relationship between TPX2 and microRNA (miR)-29c-3p was verified using TargetScan and luciferase reporter assays. Kaplan-Meier survival anal...
Source: Oncology Letters - March 28, 2022 Category: Cancer & Oncology Authors: Dongsheng Zhu Xiangfei Xu Ming Zhang Tong Wang Source Type: research

GABPB1-AS1 Promotes the Development of Osteosarcoma by Targeting SP1 and Activating the Wnt/ < em > β < /em > -Catenin Pathway
This study suggested that GABPB1-AS1 plays a carcinogenic role in OS through the SP1/Wnt/β-catenin signaling pathway through competitive binding and inhibition of miR-199a-3p.PMID:35342417 | PMC:PMC8956396 | DOI:10.1155/2022/8468896
Source: Journal of Oncology - March 28, 2022 Category: Cancer & Oncology Authors: Jingyang Chen Meiru Bian Lingxiao Pan Chengdong Liu Hanshi Yang Source Type: research

Single-cell RNA profiling identifies diverse cellular responses to EWSR1/FLI1 downregulation in Ewing sarcoma cells
ConclusionsWe show that time-dependent changes induced by suppression of oncogenicEWSR1/FLI1 expression induces dormancy, with different subpopulation dynamics. Cells re-entering the proliferative cycle show enhanced stem-like characteristics, whereas those remaining dormant for prolonged periods appear to survive through autophagy. Cells with these characteristics identified in exponentially growing cell populations and in tumor xenografts may confer drug resistance and could potentially contribute to metastasis.
Source: Cellular Oncology - January 7, 2022 Category: Cancer & Oncology Source Type: research

IRE1 α-XBP1 but not PERK inhibition exerts anti-tumor activity in osteosarcoma
In this study, we investigated the functions of endoplasmic reticulum (ER) stress activities in OS and elucidated whether ER stress inhibitors could exert antitumor effects. The expression of 84 key genes associated with unfolded protein response (UPR) was assessed in four OS cells (143B, MG63, U2OS and KHOS) by RT2 Profiler PCR Arrays. Based on results, we performed both siRNA and inhibitor assays focusing on IRE1 α-XBP1 and PERK pathways. All OS cell lines showed resistance to PERK inhibitors. Furthermore,ATF4 andEIF2A inhibition by siRNA did not affect the survival of OS cell lines. On the other hand, IRE1 α-XBP1 inhi...
Source: Hormones and Cancer - November 30, 2021 Category: Cancer & Oncology Source Type: research

Posttranscriptional inhibition of γ-adducin promotes the proliferation and migration of osteosarcoma cells
CONCLUSIONS: Our study found that ADD3 functioned as a tumor suppressor gene during osteosarcoma development. The abnormal upregulation of miR-23b-3p targeted the expression of ADD3 and resulted in accelerated osteosarcoma cell proliferation and migration. Thus, the miR-23b-3p/ADD3 axis contributes to the development of osteosarcoma and ADD3 is a key driver of malignancy.PMID:34632867 | DOI:10.1177/03008916211050687
Source: Tumori - October 11, 2021 Category: Cancer & Oncology Authors: Zhigang Suo Xiucai Ma Yueping Ding Yu Zhou Xiangguo Duan Le Fei Jianmin Song Huiqiang Ding Source Type: research

Pages: 1 2 3 4 5 6 7 8